Treating Atopic Dermatitis in Young Children: What's New, What's True?

The discussion revolves around the treatment of atopic dermatitis (AD) in young children, emphasizing the evolving treatment landscape. The objectives include reviewing topical medications, analyzing safety and efficacy data of topical steroids, and discussing newer therapeutic options. Atopic dermatitis is prevalent, significantly affecting the quality of life for both children and caregivers. The treatment approach follows a therapeutic ladder, starting with emollients and gentle skin care, progressing to topical corticosteroids and other steroid-sparing options, and eventually considering systemic agents. The speaker highlights the importance of proper steroid use, as many parents are concerned about their potential for skin atrophy and systemic absorption. Extensive safety data support the use of medium-potency topical steroids like fluticasone in young patients. Proper dosage is critical, as many children are often under-treated due to inadequate medication amounts. Non-steroidal options, including calcineurin inhibitors and PDE4 inhibitors, are presented as alternatives, especially for sensitive areas. Recent advancements include the introduction of targeted therapies such as biologics and JAK inhibitors, offering hope for patients with severe AD. The speaker stresses the importance of moving from flare management to maintenance therapy to prevent recurrences and improve long-term outcomes. The rapid increase in treatment modalities means that practitioners can better customize care for young patients.